Serial Coagulation Monitoring in Veterinary Patients: Indications and Interpretation

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Serial coagulation monitoring, by tracking trends in parameters like PT, aPTT, platelet count, and D-dimer, is crucial for managing dynamic hemostatic disorders such as DIC and anticoagulant rodenticide toxicity, offering more clinical insight than single measurements.
• Factor VII's short half-life makes serial PT the earliest indicator of vitamin K deficiency or antagonism, while factor consumption in DIC often leads to concurrent PT and aPTT prolongation, necessitating a panel approach.
• The transition from a compensated to a decompensated coagulopathy, often preceding clinical bleeding, is detectable through serial monitoring of PT, aPTT, and platelet counts, signaling the need for active therapeutic intervention.
• Consistent laboratory methodology, including the same analyzer and sample type, is paramount for valid serial comparisons; underfilled citrate tubes, hemolysis, and lipemia can create misleading trends and necessitate repeat testing.
• In DIC, rising D-dimer with falling fibrinogen and platelets indicates ongoing consumption, while stable or falling D-dimer suggests control; serial antithrombin levels are vital for identifying thrombotic risk in hypercoagulable states like severe trauma.
• Monitoring intervals should be adjusted based on clinical stability and disease kinetics, with acutely unstable patients requiring testing every 6-12 hours, while stable patients with rodenticide toxicity may only need daily PT checks.

Serial coagulation monitoring refers to the repeated measurement of hemostatic parameters over time to track disease progression, guide therapeutic decisions, and detect complications before they become clinically apparent. This article addresses the practicing veterinarian's need to interpret changing coagulation profiles in dogs and cats with conditions such as disseminated intravascular coagulation (DIC), anticoagulant rodenticide toxicity, and other acquired or inherited coagulopathies. The focus is on using trends instead of single values to direct therapy, adjust monitoring intervals, and refine prognoses.

A single coagulation panel provides a snapshot. Serial testing provides a trajectory, and that trajectory frequently carries more clinical weight than any individual result. The distinction matters because hemostasis is a dynamic system with competing procoagulant and anticoagulant forces. A patient with a normal prothrombin time (PT) on admission may develop prolongation within hours as clotting factors are consumed, and a patient with a prolonged PT may improve with vitamin K therapy at a rate that predicts outcome. Understanding the physiology that drives these changes is the foundation for interpreting serial results.

At a Glance

Physiology of Serial Coagulation Changes

The hemostatic system balances procoagulant, anticoagulant, and fibrinolytic forces. When this balance shifts, laboratory values change in predictable sequences. In endotoxemia models, tissue factor activity from peripheral blood mononuclear cells rises within hours, followed by thrombin generation and fibrin monomer formation, then by consumption of antithrombin and fibrinogen Kutzsche et al. documented these temporal relationships in a controlled porcine endotoxemia model. The sequence matters clinically: early markers of thrombin generation appear before global tests like PT and aPTT prolong, and they resolve or worsen on a different time course.

Fibrin degradation products and D-dimer reflect the fibrinolytic response to fibrin deposition. In experimental DIC, D-dimer rises early and remains elevated, reflecting ongoing lysis of microvascular fibrin deposits the relationship between fibrin degradation products, fibrin monomer, and soluble fibrin in DIC is reviewed in detail by Horan and Francis. A normal D-dimer has high negative predictive value for DIC, which makes serial D-dimer measurement useful for ruling out ongoing disseminated coagulation when results remain normal.

Factor Half-Lives and Test Sensitivity

Factor VII has the shortest half-life of the vitamin K dependent factors, approximately 4 to 6 hours. PT therefore prolongs earliest in vitamin K deficiency or antagonism. Factor IX and factor X have longer half-lives, so aPTT prolongation follows PT prolongation in anticoagulant rodenticide toxicity. Serial PT measurement is the most sensitive way to detect early toxicity and to confirm adequate response to vitamin K therapy. In DIC, by contrast, factor consumption affects multiple pathways simultaneously, and PT and aPTT often prolong together.

The Concept of Compensated Versus Decompensated Coagulopathy

Early in consumptive coagulopathy, the liver and bone marrow can compensate for factor and platelet losses. Laboratory values may remain within reference intervals despite ongoing activation. As compensation fails, PT and aPTT prolong, platelet counts fall, and fibrinogen declines. Serial monitoring detects the transition from compensated to decompensated state, which often precedes clinical bleeding. This transition is the point at which therapeutic intervention changes from monitoring to active treatment.

Laboratory Considerations for Serial Testing

Serial comparisons are only valid when testing conditions remain consistent. The American Society for Veterinary Clinical Pathology publishes quality assurance guidelines covering reference intervals, method validation, and quality control procedures that laboratories should follow ASVCP quality assurance and laboratory standards guidance. For serial monitoring, the clinician should use the same laboratory, the same analyzer, and ideally the same sample type throughout a patient's course. Point-of-care analyzers may produce results that differ from reference laboratory values, and switching between methods mid-treatment can create apparent trends that do not reflect the patient's true status.

Sample handling affects coagulation testing more than most laboratory assays. Underfilled citrate tubes alter the citrate to blood ratio and prolong clotting times. Hemolyzed, lipemic, or clotted samples produce unreliable results. For serial monitoring, a single poorly handled sample can generate a false trend that leads to inappropriate therapy. When a result does not fit the clinical picture, repeat testing before changing treatment.

Indications for Serial Coagulation Monitoring

Disseminated Intravascular Coagulation

DIC is a dynamic process, and a single coagulation panel cannot distinguish between a patient who is improving, stable, or deteriorating. Serial monitoring tracks the balance between thrombin generation and consumption. The typical monitoring protocol measures PT, aPTT, platelet count, fibrinogen, and D-dimer at intervals of 6 to 12 hours during the acute phase, then daily as the patient stabilizes. The pattern of change matters more than any single value. Rising D-dimer with falling fibrinogen and platelets indicates ongoing consumption. Stable or falling D-dimer with stable platelet count suggests the process is controlled.

Anticoagulant Rodenticide Toxicity

Serial PT is the central element of monitoring in anticoagulant rodenticide toxicity. After initiating vitamin K therapy, PT should be rechecked at 48 to 72 hours to confirm that the extrinsic pathway has normalized. Prolongation at this point indicates inadequate dosing, ongoing exposure, or malabsorption. After completing the recommended course of vitamin K, PT is typically rechecked at 3 to 7 days after discontinuation to detect rebound prolongation. The duration of monitoring depends on the specific anticoagulant ingested, and current formulary references should be consulted for species specific recommendations.

Traumatic Brain Injury and Hypercoagulable States

Severe tissue injury triggers systemic coagulation activation. In human patients with severe traumatic brain injury, antithrombin levels fall below normal within the first 24 to 48 hours, and a substantial proportion develop increased clot firmness on viscoelastic testing Kalgudi and Ho documented reduced antithrombin levels and elevated clot firmness in a prospective cohort of severe TBI patients. Serial antithrombin measurement can identify patients at risk for thromboembolic complications and guide the timing of thromboprophylaxis. The same principles apply to veterinary patients with major trauma, burns, or sepsis, although species specific reference intervals must be used.

Thermal Burn Injury

Burn injury produces a hypercoagulable state with measurable cardiovascular and coagulation effects. Cats with thermal burn injuries from wildfires showed myocardial thickening and intracardiac thrombus formation on serial echocardiography Sharpe et al. described these findings in naturally exposed burn patients. Serial coagulation monitoring in burn patients should include markers of thrombin generation and fibrinolysis, as these patients are at risk for both thrombotic and hemorrhagic complications.

Interpretation Frameworks

Serial coagulation data are best interpreted using trend analysis instead of comparison to reference intervals alone. A platelet count that falls from 300,000 to 150,000 per microliter over 24 hours may remain within the reference interval but represents a 50 percent decline that demands investigation. Conversely, a PT that remains stable at 1.5 times the upper reference limit across three measurements may indicate a compensated state that does not require escalating therapy.

The rate of change provides information about the underlying process. Rapid deterioration over hours suggests ongoing consumption or acute hemorrhage. Slow drift over days suggests chronic disease, nutritional deficiency, or progressive bone marrow failure. The direction of change after therapeutic intervention indicates whether treatment is working. PT that shortens after vitamin K administration confirms the diagnosis of vitamin K deficiency or antagonism. PT that fails to shorten suggests ongoing exposure, inadequate dose, or a different cause of coagulopathy.

Serial monitoring intervals should be adjusted based on clinical stability. A hemodynamically unstable patient with active bleeding requires testing every 6 to 12 hours. A stable patient with known rodenticide toxicity may only require daily PT checks. The monitoring interval should be shortened whenever the clinical picture changes, and lengthened only when results have been stable across multiple measurements.

Recheck Intervals and Decision Points

The interval between coagulation measurements should be dictated by the trajectory of the underlying disease, the half-lives of the factors being replaced or consumed, and the specific therapeutic intervention in place. A fixed recheck schedule applied to all patients will misclassify both rapid deterioration and slow recovery.

For patients with suspected or confirmed disseminated intravascular coagulation (DIC), the acute phase demands frequent reassessment. In experimental endotoxemia models, thrombin-antithrombin complex concentrations peak within hours of the inciting stimulus, and fibrin monomer becomes detectable shortly thereafter, indicating that meaningful changes in coagulation status occur on a timescale of hours, not days. Clinical extrapolation supports rechecking coagulation panels every 6 to 12 hours in the unstable patient with active DIC, particularly when fresh frozen plasma or other supportive therapy is being titrated. Once the patient stabilizes hemodynamically and the underlying trigger is controlled, the interval can be extended to every 24 hours, then to every 48 to 72 hours as trends normalize.

For anticoagulant rodenticide toxicity, the recheck interval is governed by the vitamin K1 treatment protocol and the expected recovery of vitamin K dependent factor activity. Prothrombin time (PT) should be rechecked 48 to 72 hours after cessation of vitamin K1 therapy to confirm that factor activity has not fallen back into the prolonged range. During the initial treatment phase, PT can be rechecked every 24 to 48 hours to document a response to therapy, although most patients will show improvement within 24 hours of adequate vitamin K1 administration. Patients with suspected re-exposure or with very high initial PT values warrant the longer monitoring window after therapy withdrawal.

Monitoring Parameters by Clinical Context

The choice of which coagulation parameters to follow serially should match the pathophysiology being tracked. No single test captures the full hemostatic state, and the limitations of each assay become more consequential when results are interpreted as trends.

D-dimer and soluble fibrin assays are highly sensitive for fibrin formation and lysis, and a normal result carries strong negative predictive value for ongoing DIC. Serial monitoring of these markers can therefore be used to confirm that the coagulopathy is resolving. However, assay standardization varies between platforms, and quantitative results from different analyzers should not be compared directly. Trends are only interpretable when the same laboratory and method are used throughout the monitoring period.

Antithrombin measurement deserves specific mention. In severe traumatic brain injury, antithrombin levels fall below the reference interval in a substantial proportion of patients within the first 24 to 48 hours, and this reduction may precede clinically evident thromboembolism. Serial antithrombin measurement can identify patients at heightened thrombotic risk who might benefit from more aggressive thromboprophylaxis, although the evidence base for specific interventions in veterinary patients remains limited.

Protocol Structure for Serial Testing

A structured protocol reduces the risk of missed samples and improves the interpretability of trends. The following sequence applies to most hospitalized patients requiring serial coagulation monitoring.

First, establish a baseline panel at presentation or at the time of suspected coagulopathy. This panel should include platelet count, PT, activated partial thromboplastin time (aPTT), fibrinogen, and a fibrin degradation product assay. Antithrombin should be included when DIC or a hypercoagulable state is suspected. The baseline sample establishes the reference point against which all subsequent changes are judged.

Second, define the recheck interval based on the clinical context as outlined in the table above. Document the planned interval in the medical record so that all members of the treatment team follow the same schedule.

Third, at each recheck, compare the current values to both the reference interval and the previous values. The rate of change often carries more diagnostic weight than the absolute value. A platelet count falling from 200,000 to 120,000 per microliter over 12 hours is more concerning than a stable count of 100,000 per microliter.

Fourth, adjust therapy based on the trend. For example, a patient with DIC whose PT and aPTT are progressively prolonging despite plasma support may require more aggressive replacement or reconsideration of the underlying trigger. A patient with rodenticide toxicity whose PT is improving on vitamin K1 can be transitioned to less frequent monitoring.

Documentation and Communication of Trends

Serial coagulation data should be recorded in a format that makes trends immediately visible. A simple table in the medical record listing date, time, and each parameter allows rapid visual assessment. Graphic representation, where the medical record system supports it, is particularly useful for tracking parameters such as platelet count and D-dimer over several days.

The interpretation of trends should be documented explicitly. A note that states "PT prolonged at 25 seconds, up from 18 seconds 12 hours ago, consistent with ongoing consumption" is more useful than a note that simply lists the current value. This documentation supports clinical decision-making and provides a clear record for other clinicians assuming care of the patient.

Communication with the laboratory is also important. If the patient is being monitored across multiple shifts or days, confirm that the same analyzer and reagent lot are in use. Changes in reagent lots can shift PT and aPTT results independently of the patient's clinical status, and the ASVCP quality assurance guidelines emphasize the importance of consistent methodology when results are compared over time.

Species and Equipment Considerations

The correct monitoring approach differs between dogs and cats in several respects. Cats with thermal burn injuries have demonstrated a high prevalence of myocardial thickening and intracardiac thrombus formation, with spontaneous echocardiographic contrast identified in a substantial proportion of affected animals. This finding suggests that echocardiographic assessment should be incorporated into the serial monitoring plan for burned cats, in addition to standard coagulation testing. The same recommendation does not currently apply to burned dogs with the same force of evidence.

Point-of-care coagulation analyzers are widely used in general practice and can support serial monitoring when in-house testing is required. These devices are acceptable for trend monitoring provided their limitations are understood. Results from point-of-care devices may not be directly comparable to reference laboratory values, and the MSD Veterinary Manual advises that clinicians establish the performance characteriztics of their specific device. For medicolegal purposes and for complex coagulopathies, confirmatory testing at a reference laboratory is advisable.

Viscoelastic testing, where available, provides additional information about clot formation and fibrinolysis that standard coagulation panels cannot capture. In experimental models, viscoelastic parameters such as maximum clot firmness increase in conjunction with fibrinogen and platelet elevations during the hypercoagulable phase of critical illness. Practices with viscoelastic capability should incorporate these results into the serial monitoring plan, particularly for patients with traumatic brain injury or other conditions associated with a hypercoagulable phase.

Recognized Complications and Early Detection

Serial coagulation monitoring carries its own failure modes. The most consequential is acting on laboratory artefact. In vitro clot formation, underfilled citrate tubes, hemolysis, lipaemia, and delayed plasma separation all distort PT and aPTT results. A prolonged aPTT that appears suddenly in a stable patient should prompt a repeat draw before any therapeutic change. The same applies to a shortening PT that suggests reagent or analyzer drift instead of genuine improvement.

The second failure mode is mistaking laboratory trend for clinical trend. Coagulation tests measure plasma proteins, not tissue perfusion, endothelial injury, or bleeding risk. A patient with improving PT and aPTT may still have ongoing consumptive coagulopathy reflected only in thrombocytopenia, rising D-dimer, or falling antithrombin. Conversely, a patient with persistently prolonged PT may be clinically stable if the defect is compensated. Serial monitoring should therefore pair coagulation times with platelet count, fibrinogen, and a fibrinolysis marker where available. The ASVCP quality assurance guidelines emphasize that method validation and reference interval verification are prerequisites for interpreting any trend, and this matters most when results guide therapy.

A third failure mode is sampling frequency that is either too low or too high. In DIC, coagulation parameters can shift within hours, as demonstrated in experimental endotoxaemia where thrombin-antithrombin complexes peaked at 3 hours and fibrin monomer rose progressively to 6 hours after infusion onset. Testing once daily may miss the transition from compensated to decompensated coagulopathy. Testing every few hours, however, invites over-treatment of transient laboratory fluctuations that carry no clinical weight. The interval should match the suspected kinetics of the underlying process and the half-life of the factor being monitored.

Common Errors and Corrective Action

Less experienced clinicians often anchor on a single abnormal value instead of the trajectory. A mildly prolonged PT in a rodenticide case is not itself an indication to escalate therapy if the trend is downward and the patient is stable. The corrective action is to plot at least two, ideally three, consecutive values and assess slope, not level.

A second error is interpreting PT and aPTT as interchangeable. PT reflects the extrinsic and common pathways, aPTT the intrinsic and common pathways. In early DIC, aPTT may be normal or even shortened due to circulating activated factors, while PT prolongs later. In rodenticide toxicity, PT typically prolongs before aPTT because factor VII has the shortest half-life. Expecting both to move together leads to delayed recognition of early disease.

A third error is ignoring the platelet count when interpreting coagulation times. DIC is a consumptive process, a falling platelet count often precedes prolongation of PT or aPTT. Serial monitoring protocols that omit platelet counts forfeit the earliest available signal of ongoing consumption.

A fourth error is failing to standardize the timing of samples relative to treatment. Vitamin K therapy in rodenticide toxicity shortens PT over 24 to 48 hours, and samples drawn too early may falsely suggest treatment failure. Samples drawn after transfusion reflect the transfused factors as much as endogenous production. Document the time of the last dose or transfusion on the laboratory submission.

Limitations of the Evidence and Areas of Disagreement

The veterinary evidence base for serial coagulation monitoring is largely extrapolated from human medicine and experimental models. The fibrin degradation product and soluble fibrin literature is drawn primarily from human DIC, and the controlled endotoxaemia model is porcine. Both provide useful kinetic frameworks, but neither establishes species-specific decision thresholds for dogs and cats.

Expert opinion differs on how aggressively to treat laboratory abnormalities in the absence of clinical bleeding. Some clinicians treat a rising D-dimer or falling antithrombin with plasma or anticoagulants even when PT and aPTT are normal. Others restrict treatment to patients with overt hemorrhage or documented prolongation of coagulation times. The evidence does not currently resolve this disagreement, and the MSD Veterinary Manual reflects this by presenting monitoring recommendations as guidance instead of fixed protocols.

There is also genuine uncertainty about the clinical significance of hypercoagulable trends detected by viscoelastic testing. Experimental work in traumatic brain injury shows that antithrombin deficiency and increased clot firmness occur in a substantial proportion of patients, yet the relationship to thromboembolic events was not statistically significant in that cohort. Whether early detection of these trends should alter therapy remains an open question.

Troubleshooting and Failure-Mode Table

Referral, Consultation, and Reporting

Referral to a specialist is warranted when the trend is worsening despite treatment, when the pattern of abnormalities does not fit a recognized syndrome, or when viscoelastic testing is needed to characterize a hypercoagulable state. Laboratory consultation is appropriate when results are discordant with the clinical picture or when method-related artefacts are suspected. The clinical pathologist can advise on sample handling, assay selection, and interpretation of borderline values.

Regulatory reporting applies to suspected anticoagulant rodenticide exposure where public health or environmental contamination is possible, and to any case involving food-producing animals where withdrawal periods or trade implications arise. The WOAH terrestrial animal health standards and AVMA practice resources provide guidance on the relevant obligations. When in doubt, contact the appropriate authority before the case is closed.

Frequently Asked Questions

How Should I Prioritize Serial Coagulation Testing When Budget or Equipment Is Limited?

When resources are constrained, prioritize the test that answers the most urgent clinical question. For suspected DIC, serial platelet count and D-dimer or fibrin degradation products provide the highest diagnostic yield, as marked elevations in fibrin degradation products are a constant finding in experimental DIC models per fibrin degradation product and soluble fibrin research. For anticoagulant rodenticide toxicity, prothrombin time is the most sensitive screening test. If point-of-care analyzers are unavailable, consider in-clinic platelet estimation and blood film review, then send citrated plasma to a reference laboratory. Establish a minimum database that can be repeated consistently, even if it is only platelet count and prothrombin time, instead of performing a full panel once and then being unable to repeat it.

What Is the Minimum Frequency for Rechecking Coagulation in a Stable Patient on Anticoagulant Therapy?

For stable patients receiving anticoagulant therapy, recheck intervals depend on the drug and the target of therapy. Vitamin K antagonist therapy requires prothrombin time monitoring every 24 to 48 hours until a stable dose is achieved, then weekly to monthly. Heparin therapy requires more frequent monitoring, often every 6 to 12 hours initially, because of its short half-life and variable pharmacokinetics. The MSD Veterinary Manual provides species-specific guidance on expected response times and monitoring frequency. If the patient is clinically stable with two consecutive therapeutic results, intervals can be extended. Any change in body weight, appetite, or concurrent medication should prompt an earlier recheck, as these factors alter drug metabolism and clearance.

How Do Serial Coagulation Results Differ Between Dogs and Cats in DIC?

Cats with DIC frequently show a different laboratory profile than dogs. Cats often maintain normal or elevated fibrinogen concentrations despite ongoing consumptive coagulopathy, and their platelet counts may remain within reference intervals until late in the disease. This makes serial monitoring of a single parameter unreliable in cats. A panel approach, including platelet count, prothrombin time, activated partial thromboplastin time, and D-dimer, is more informative. Cats also have a higher incidence of arterial thromboembolism as a complication of underlying cardiac disease, and echocardiographic evidence of intracardiac thrombi has been documented in cats with systemic illness, as described in cats with thermal burn injuries from California wildfires. Trending multiple parameters over time is therefore essential in cats, as single-point abnormalities are poorly specific.

What Should I Document in the Medical Record for Serial Coagulation Monitoring?

Record the exact time of sample collection, the analyzer used, and the reference interval for that analyzer, as results vary between point-of-care and reference laboratory methods. Document the clinical indication for testing, the current therapy and dose, and the time of the last dose of any anticoagulant. For each result, note the trend relative to the previous value, also the absolute number. The American Society for Veterinary Clinical Pathology quality assurance guidelines emphasize that method validation and reference intervals are laboratory-specific, so document which laboratory or analyzer generated each result. Also record any transfusion products administered between samples, as these alter coagulation test results and must be considered when interpreting trends.

How Do I Explain Serial Monitoring to a Client Who Is Concerned About Cost?

Frame serial monitoring as a cost-control measure, not an additional expense. Explain that a single coagulation test provides a snapshot, while serial testing shows whether treatment is working or failing. For rodenticide toxicity, a single normal prothrombin time after treatment does not confirm recovery, and premature discharge can lead to fatal rebleeding. For DIC, serial testing allows earlier detection of deterioration, potentially avoiding costly intensive care later. Offer a tiered plan, such as a minimum database for each recheck, and explain what each tier adds diagnostically. The American Veterinary Medical Association practice resources offer guidance on communicating value of diagnostic testing to clients. Be transparent that monitoring may be discontinued if the clinical picture stabilizes, and that the frequency of testing will decrease as trends become predictable.

When Should I Stop Serial Monitoring and Transition to a Different Diagnostic Approach?

Stop serial coagulation monitoring when the trend has been stable for two consecutive sampling intervals and the underlying disease is resolving. For DIC, transition to monitoring organ function and perfusion parameters once coagulation parameters have normalized, as ongoing organ dysfunction may reflect established microthrombosis instead of active consumption. For rodenticide toxicity, discontinue monitoring when prothrombin time has been normal for 48 to 72 hours after cessation of vitamin K therapy. If the patient deteriorates despite apparently improving coagulation trends, reassess the diagnosis instead of repeating the same tests. Consider viscoelastic testing if available, as standard coagulation tests do not detect hypercoagulability, which may follow the consumptive phase of DIC, as noted in antithrombin deficiency after severe traumatic brain injury. Escalate to referral if the pattern remains ambiguous after three sampling points.

Related Clinical & Scientific Guides

• Peripheral Blood Smear Evaluation: A Step-by-Step Guide
• Reticulocyte Counts in Veterinary Medicine: Clinical Utility and Interpretation
• Cerebrospinal Fluid Analysis in Veterinary Neurology: Collection and Interpretation

References and Further Reading

• Cats with thermal burn injuries from California wildfires show echocardiographic evidence of myocardial thickening and intracardiac thrombi.. 2020.
• Incidence of Antithrombin Deficiency and Anti-Cardiolipin Antibodies After Severe Traumatic Brain Injury: A Prospective Cohort Study.. 2021.
• ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia.. 2011.
• Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.. 2001.
• Hemodynamic changes and systemic activation of coagulation and fibrinolysis during controlled endotoxemia in pigs.. 2000.
• American Society for Veterinary Clinical Pathology Guidelines. American Society for Veterinary Clinical Pathology.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Monitoring Hematologic Recovery After Chemotherapy in Veterinary Patients
• Bone Marrow Aspiration and Biopsy: Indications and Interpretation
• Monitoring Coagulation Status in Anticoagulant Rodenticide Toxicity
• Monitoring Serum Lactate in Critically Ill Veterinary Patients
• Serial Urinalysis in Monitoring Urinary Tract Infections

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.